East China Pharmaceuticals introduces dual-specific antibody PRV-3279 for development rights and interests in Greater China

PRV-3279 is a humanized dual antibody (a DART® dual-specific antibody for B cell surface proteins CD32B and CD79B.
in combination with CD32B and CD79B triggers inhibition of B cell function and autoantibodies, thus regulating B cells without causing B cell depletion.
Bio is developing PRV-3279 to block systemic lupus erythematosus (SLE), which is in Phase I in the United States.
SLE is a chronic autoimmune disease characterized by over-active B cells and pathological production of autoantibodies.
PRV-3279 also has the potential to prevent or reduce immunogenicity (including, but not limited to, gene therapy vectors and genetically modified organisms) in biological therapy, in the preclinical stage.
Under the terms of the agreement, Provention Bio will receive an advance of $6 million from East China Pharmaceuticals and $11.5 million over the next three years to advance research and development and production of the PRV-3279, with future milestone payments of up to $172 million upon registration and commercial milestones.
Product Bio will also receive a tiered, double-digit net sales fee.
East China Pharmaceuticals will be responsible for the clinical development and commercialization of PRV-3279 in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan), and the two companies will establish a joint steering committee.
DevelopmentBio will continue to be responsible for the clinical development and commercialization of prV-3279 in the United States and other regions.
note: There are deletions in the original text